nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2J2—Cholecalciferol—psoriasis	0.344	0.438	CbGbCtD
Levomilnacipran—CYP2C8—Tazarotene—psoriasis	0.0563	0.0718	CbGbCtD
Levomilnacipran—CYP2D6—Hydroxyurea—psoriasis	0.0253	0.0323	CbGbCtD
Levomilnacipran—CYP2C8—Cholecalciferol—psoriasis	0.024	0.0306	CbGbCtD
Levomilnacipran—CYP2C8—Mycophenolate mofetil—psoriasis	0.0208	0.0266	CbGbCtD
Levomilnacipran—CYP2C19—Cholecalciferol—psoriasis	0.0202	0.0257	CbGbCtD
Levomilnacipran—CYP3A4—Calcitriol—psoriasis	0.0189	0.0241	CbGbCtD
Levomilnacipran—CYP2C8—Hydrocortisone—psoriasis	0.0167	0.0213	CbGbCtD
Levomilnacipran—CYP2C8—Cyclosporine—psoriasis	0.0158	0.0201	CbGbCtD
Levomilnacipran—CYP2D6—Cholecalciferol—psoriasis	0.0153	0.0195	CbGbCtD
Levomilnacipran—CYP3A4—Methoxsalen—psoriasis	0.0147	0.0188	CbGbCtD
Levomilnacipran—ABCB1—Mycophenolate mofetil—psoriasis	0.0141	0.018	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—psoriasis	0.014	0.0178	CbGbCtD
Levomilnacipran—CYP2C19—Cyclosporine—psoriasis	0.0133	0.0169	CbGbCtD
Levomilnacipran—ABCB1—Betamethasone—psoriasis	0.0121	0.0154	CbGbCtD
Levomilnacipran—ABCB1—Prednisolone—psoriasis	0.0119	0.0152	CbGbCtD
Levomilnacipran—ABCB1—Hydrocortisone—psoriasis	0.0113	0.0144	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—psoriasis	0.0113	0.0144	CbGbCtD
Levomilnacipran—ABCB1—Cyclosporine—psoriasis	0.0107	0.0136	CbGbCtD
Levomilnacipran—CYP2C8—Dexamethasone—psoriasis	0.0104	0.0133	CbGbCtD
Levomilnacipran—CYP2D6—Cyclosporine—psoriasis	0.0101	0.0128	CbGbCtD
Levomilnacipran—CYP3A4—Cholecalciferol—psoriasis	0.00975	0.0124	CbGbCtD
Levomilnacipran—CYP2C19—Dexamethasone—psoriasis	0.00873	0.0111	CbGbCtD
Levomilnacipran—CYP3A4—Mycophenolate mofetil—psoriasis	0.00846	0.0108	CbGbCtD
Levomilnacipran—CYP3A4—Triamcinolone—psoriasis	0.00846	0.0108	CbGbCtD
Levomilnacipran—CYP3A4—Betamethasone—psoriasis	0.00725	0.00924	CbGbCtD
Levomilnacipran—CYP3A4—Prednisolone—psoriasis	0.00716	0.00912	CbGbCtD
Levomilnacipran—ABCB1—Dexamethasone—psoriasis	0.00704	0.00897	CbGbCtD
Levomilnacipran—CYP3A4—Hydrocortisone—psoriasis	0.00679	0.00865	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—psoriasis	0.00676	0.00861	CbGbCtD
Levomilnacipran—CYP2D6—Dexamethasone—psoriasis	0.00664	0.00845	CbGbCtD
Levomilnacipran—CYP3A4—Cyclosporine—psoriasis	0.00641	0.00816	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—psoriasis	0.00566	0.00721	CbGbCtD
Levomilnacipran—CYP2J2—Xenobiotics—CYP2S1—psoriasis	0.00431	0.124	CbGpPWpGaD
Levomilnacipran—CYP3A4—Dexamethasone—psoriasis	0.00422	0.00538	CbGbCtD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00179	0.0515	CbGpPWpGaD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00177	0.0508	CbGpPWpGaD
Levomilnacipran—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00174	0.0499	CbGpPWpGaD
Levomilnacipran—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00155	0.0446	CbGpPWpGaD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00145	0.0417	CbGpPWpGaD
Levomilnacipran—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00143	0.041	CbGpPWpGaD
Levomilnacipran—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00133	0.0382	CbGpPWpGaD
Levomilnacipran—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00108	0.0309	CbGpPWpGaD
Levomilnacipran—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000961	0.0276	CbGpPWpGaD
Levomilnacipran—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000884	0.0254	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—CYP2S1—psoriasis	0.000771	0.0222	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP2S1—psoriasis	0.00076	0.0219	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL22—psoriasis	0.000752	0.0216	CbGpPWpGaD
Levomilnacipran—CYP2J2—Tryptophan metabolism—CAT—psoriasis	0.000665	0.0191	CbGpPWpGaD
Levomilnacipran—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000578	0.0166	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000447	0.0128	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000441	0.0127	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000399	0.0115	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000394	0.0113	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000367	0.0105	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000362	0.0104	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000362	0.0104	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000323	0.0093	CbGpPWpGaD
Levomilnacipran—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000311	0.00895	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000308	0.00886	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000297	0.00855	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000275	0.0079	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000247	0.00709	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00024	0.0069	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000237	0.00681	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000217	0.00624	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000212	0.00609	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000194	0.00559	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000192	0.00553	CbGpPWpGaD
Levomilnacipran—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000192	0.00551	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.00019	0.00546	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000185	0.00531	CbGpPWpGaD
Levomilnacipran—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000184	0.00528	CbGpPWpGaD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000179	0.00514	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000172	0.00494	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000169	0.00487	CbGpPWpGaD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000167	0.00479	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000158	0.00454	CbGpPWpGaD
Levomilnacipran—SLC6A2—Monoamine Transport—TNF—psoriasis	0.000158	0.00454	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000156	0.00448	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NDUFA5—psoriasis	0.000155	0.00446	CbGpPWpGaD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000153	0.0044	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000145	0.00416	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000143	0.0041	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL13—psoriasis	0.000142	0.00407	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	0.00014	0.00403	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000136	0.0039	CbGpPWpGaD
Levomilnacipran—Tachycardia—Hydrocortisone—psoriasis	0.000134	0.000746	CcSEcCtD
Levomilnacipran—Somnolence—Mycophenolate mofetil—psoriasis	0.000134	0.000746	CcSEcCtD
Levomilnacipran—Flushing—Prednisone—psoriasis	0.000134	0.000743	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000134	0.000742	CcSEcCtD
Levomilnacipran—Skin disorder—Hydrocortisone—psoriasis	0.000134	0.000742	CcSEcCtD
Levomilnacipran—Fatigue—Cyclosporine—psoriasis	0.000134	0.000741	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Hydrocortisone—psoriasis	0.000133	0.000739	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000133	0.000739	CcSEcCtD
Levomilnacipran—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000133	0.000738	CcSEcCtD
Levomilnacipran—Constipation—Cyclosporine—psoriasis	0.000133	0.000735	CcSEcCtD
Levomilnacipran—Dry mouth—Triamcinolone—psoriasis	0.000132	0.000734	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—CYP2S1—psoriasis	0.000132	0.00379	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000131	0.000729	CcSEcCtD
Levomilnacipran—Anorexia—Hydrocortisone—psoriasis	0.000131	0.000728	CcSEcCtD
Levomilnacipran—Diarrhoea—Mycophenolic acid—psoriasis	0.000131	0.000727	CcSEcCtD
Levomilnacipran—Angiopathy—Prednisone—psoriasis	0.000131	0.000726	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000131	0.000724	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL17A—psoriasis	0.00013	0.00375	CbGpPWpGaD
Levomilnacipran—Syncope—Dexamethasone—psoriasis	0.000129	0.000717	CcSEcCtD
Levomilnacipran—Syncope—Betamethasone—psoriasis	0.000129	0.000717	CcSEcCtD
Levomilnacipran—Constipation—Mycophenolate mofetil—psoriasis	0.000129	0.000717	CcSEcCtD
Levomilnacipran—Infection—Triamcinolone—psoriasis	0.000129	0.000715	CcSEcCtD
Levomilnacipran—Hypotension—Hydrocortisone—psoriasis	0.000129	0.000714	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—psoriasis	0.000128	0.00071	CcSEcCtD
Levomilnacipran—Shock—Triamcinolone—psoriasis	0.000128	0.000708	CcSEcCtD
Levomilnacipran—Insomnia—Prednisolone—psoriasis	0.000128	0.000708	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—psoriasis	0.000127	0.000705	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Cyclosporine—psoriasis	0.000127	0.000703	CcSEcCtD
Levomilnacipran—Loss of consciousness—Betamethasone—psoriasis	0.000127	0.000703	CcSEcCtD
Levomilnacipran—Loss of consciousness—Dexamethasone—psoriasis	0.000127	0.000703	CcSEcCtD
Levomilnacipran—Dizziness—Mycophenolic acid—psoriasis	0.000127	0.000703	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisolone—psoriasis	0.000127	0.000703	CcSEcCtD
Levomilnacipran—Tachycardia—Triamcinolone—psoriasis	0.000127	0.000702	CcSEcCtD
Levomilnacipran—Mental disorder—Prednisone—psoriasis	0.000126	0.000701	CcSEcCtD
Levomilnacipran—Malnutrition—Prednisone—psoriasis	0.000126	0.000697	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Triamcinolone—psoriasis	0.000125	0.000696	CcSEcCtD
Levomilnacipran—Convulsion—Dexamethasone—psoriasis	0.000125	0.000693	CcSEcCtD
Levomilnacipran—Convulsion—Betamethasone—psoriasis	0.000125	0.000693	CcSEcCtD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000125	0.00358	CbGpPWpGaD
Levomilnacipran—Insomnia—Hydrocortisone—psoriasis	0.000125	0.000691	CcSEcCtD
Levomilnacipran—Hypertension—Betamethasone—psoriasis	0.000125	0.000691	CcSEcCtD
Levomilnacipran—Hypertension—Dexamethasone—psoriasis	0.000125	0.000691	CcSEcCtD
Levomilnacipran—Paraesthesia—Hydrocortisone—psoriasis	0.000124	0.000686	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000124	0.000686	CcSEcCtD
Levomilnacipran—Urticaria—Cyclosporine—psoriasis	0.000123	0.000683	CcSEcCtD
Levomilnacipran—Body temperature increased—Cyclosporine—psoriasis	0.000123	0.00068	CcSEcCtD
Levomilnacipran—Abdominal pain—Cyclosporine—psoriasis	0.000123	0.00068	CcSEcCtD
Levomilnacipran—Anxiety—Dexamethasone—psoriasis	0.000122	0.000679	CcSEcCtD
Levomilnacipran—Anxiety—Betamethasone—psoriasis	0.000122	0.000679	CcSEcCtD
Levomilnacipran—Vomiting—Mycophenolic acid—psoriasis	0.000122	0.000676	CcSEcCtD
Levomilnacipran—Dyspepsia—Hydrocortisone—psoriasis	0.000121	0.000673	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000121	0.00348	CbGpPWpGaD
Levomilnacipran—Rash—Mycophenolic acid—psoriasis	0.000121	0.00067	CcSEcCtD
Levomilnacipran—Dermatitis—Mycophenolic acid—psoriasis	0.000121	0.000669	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—psoriasis	0.000121	0.000669	CcSEcCtD
Levomilnacipran—Urticaria—Mycophenolate mofetil—psoriasis	0.00012	0.000666	CcSEcCtD
Levomilnacipran—Headache—Mycophenolic acid—psoriasis	0.00012	0.000666	CcSEcCtD
Levomilnacipran—Decreased appetite—Hydrocortisone—psoriasis	0.00012	0.000664	CcSEcCtD
Levomilnacipran—Body temperature increased—Mycophenolate mofetil—psoriasis	0.00012	0.000663	CcSEcCtD
Levomilnacipran—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00012	0.000663	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—psoriasis	0.000119	0.00066	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000119	0.00066	CcSEcCtD
Levomilnacipran—Fatigue—Hydrocortisone—psoriasis	0.000119	0.000659	CcSEcCtD
Levomilnacipran—Vision blurred—Prednisone—psoriasis	0.000118	0.000657	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000118	0.0034	CbGpPWpGaD
Levomilnacipran—Urethral disorder—Methotrexate—psoriasis	0.000118	0.000656	CcSEcCtD
Levomilnacipran—Insomnia—Triamcinolone—psoriasis	0.000117	0.000651	CcSEcCtD
Levomilnacipran—Infection—Betamethasone—psoriasis	0.000117	0.000649	CcSEcCtD
Levomilnacipran—Infection—Dexamethasone—psoriasis	0.000117	0.000649	CcSEcCtD
Levomilnacipran—Paraesthesia—Triamcinolone—psoriasis	0.000116	0.000646	CcSEcCtD
Levomilnacipran—Shock—Dexamethasone—psoriasis	0.000116	0.000642	CcSEcCtD
Levomilnacipran—Shock—Betamethasone—psoriasis	0.000116	0.000642	CcSEcCtD
Levomilnacipran—Dyspnoea—Triamcinolone—psoriasis	0.000116	0.000641	CcSEcCtD
Levomilnacipran—Nervous system disorder—Dexamethasone—psoriasis	0.000115	0.00064	CcSEcCtD
Levomilnacipran—Nervous system disorder—Betamethasone—psoriasis	0.000115	0.00064	CcSEcCtD
Levomilnacipran—Agitation—Prednisone—psoriasis	0.000115	0.00064	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Betamethasone—psoriasis	0.000115	0.000639	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Dexamethasone—psoriasis	0.000115	0.000639	CcSEcCtD
Levomilnacipran—Tachycardia—Betamethasone—psoriasis	0.000115	0.000637	CcSEcCtD
Levomilnacipran—Tachycardia—Dexamethasone—psoriasis	0.000115	0.000637	CcSEcCtD
Levomilnacipran—Hypersensitivity—Cyclosporine—psoriasis	0.000114	0.000633	CcSEcCtD
Levomilnacipran—Dyspepsia—Triamcinolone—psoriasis	0.000114	0.000633	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—psoriasis	0.000114	0.000632	CcSEcCtD
Levomilnacipran—Nausea—Mycophenolic acid—psoriasis	0.000114	0.000631	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Betamethasone—psoriasis	0.000114	0.000631	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Dexamethasone—psoriasis	0.000114	0.000631	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—psoriasis	0.000113	0.000625	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000113	0.000625	CcSEcCtD
Levomilnacipran—Syncope—Prednisone—psoriasis	0.000113	0.000625	CcSEcCtD
Levomilnacipran—Anorexia—Dexamethasone—psoriasis	0.000112	0.000622	CcSEcCtD
Levomilnacipran—Anorexia—Betamethasone—psoriasis	0.000112	0.000622	CcSEcCtD
Levomilnacipran—Urticaria—Prednisolone—psoriasis	0.000112	0.000622	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—psoriasis	0.000112	0.000621	CcSEcCtD
Levomilnacipran—Fatigue—Triamcinolone—psoriasis	0.000112	0.00062	CcSEcCtD
Levomilnacipran—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000111	0.000618	CcSEcCtD
Levomilnacipran—Asthenia—Cyclosporine—psoriasis	0.000111	0.000617	CcSEcCtD
Levomilnacipran—Loss of consciousness—Prednisone—psoriasis	0.00011	0.000612	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00011	0.00317	CbGpPWpGaD
Levomilnacipran—Hypotension—Betamethasone—psoriasis	0.00011	0.00061	CcSEcCtD
Levomilnacipran—Hypotension—Dexamethasone—psoriasis	0.00011	0.00061	CcSEcCtD
Levomilnacipran—Pruritus—Cyclosporine—psoriasis	0.00011	0.000608	CcSEcCtD
Levomilnacipran—Urticaria—Hydrocortisone—psoriasis	0.000109	0.000607	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—psoriasis	0.000109	0.000607	CcSEcCtD
Levomilnacipran—Abdominal pain—Hydrocortisone—psoriasis	0.000109	0.000604	CcSEcCtD
Levomilnacipran—Body temperature increased—Hydrocortisone—psoriasis	0.000109	0.000604	CcSEcCtD
Levomilnacipran—Convulsion—Prednisone—psoriasis	0.000109	0.000604	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—psoriasis	0.000109	0.000603	CcSEcCtD
Levomilnacipran—Asthenia—Mycophenolate mofetil—psoriasis	0.000109	0.000602	CcSEcCtD
Levomilnacipran—Hypertension—Prednisone—psoriasis	0.000108	0.000601	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—psoriasis	0.000108	0.0006	CcSEcCtD
Levomilnacipran—Pruritus—Mycophenolate mofetil—psoriasis	0.000107	0.000593	CcSEcCtD
Levomilnacipran—Anxiety—Prednisone—psoriasis	0.000107	0.000591	CcSEcCtD
Levomilnacipran—Insomnia—Dexamethasone—psoriasis	0.000106	0.00059	CcSEcCtD
Levomilnacipran—Insomnia—Betamethasone—psoriasis	0.000106	0.00059	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000106	0.000589	CcSEcCtD
Levomilnacipran—Diarrhoea—Cyclosporine—psoriasis	0.000106	0.000588	CcSEcCtD
Levomilnacipran—Paraesthesia—Betamethasone—psoriasis	0.000106	0.000586	CcSEcCtD
Levomilnacipran—Paraesthesia—Dexamethasone—psoriasis	0.000106	0.000586	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—psoriasis	0.000106	0.000586	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—psoriasis	0.000105	0.000582	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisolone—psoriasis	0.000104	0.000576	CcSEcCtD
Levomilnacipran—Dyspepsia—Dexamethasone—psoriasis	0.000104	0.000575	CcSEcCtD
Levomilnacipran—Dyspepsia—Betamethasone—psoriasis	0.000104	0.000575	CcSEcCtD
Levomilnacipran—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000103	0.000574	CcSEcCtD
Levomilnacipran—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000103	0.00297	CbGpPWpGaD
Levomilnacipran—Urticaria—Triamcinolone—psoriasis	0.000103	0.000572	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—psoriasis	0.000103	0.00057	CcSEcCtD
Levomilnacipran—Body temperature increased—Triamcinolone—psoriasis	0.000103	0.000569	CcSEcCtD
Levomilnacipran—Dizziness—Cyclosporine—psoriasis	0.000103	0.000569	CcSEcCtD
Levomilnacipran—Decreased appetite—Dexamethasone—psoriasis	0.000102	0.000568	CcSEcCtD
Levomilnacipran—Decreased appetite—Betamethasone—psoriasis	0.000102	0.000568	CcSEcCtD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000102	0.00293	CbGpPWpGaD
Levomilnacipran—Infection—Prednisone—psoriasis	0.000102	0.000565	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000102	0.000564	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Betamethasone—psoriasis	0.000102	0.000564	CcSEcCtD
Levomilnacipran—Hypersensitivity—Hydrocortisone—psoriasis	0.000102	0.000563	CcSEcCtD
Levomilnacipran—Fatigue—Dexamethasone—psoriasis	0.000101	0.000563	CcSEcCtD
Levomilnacipran—Fatigue—Betamethasone—psoriasis	0.000101	0.000563	CcSEcCtD
Levomilnacipran—Shock—Prednisone—psoriasis	0.000101	0.000559	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—psoriasis	0.000101	0.000558	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—psoriasis	0.0001	0.000555	CcSEcCtD
Levomilnacipran—Dizziness—Mycophenolate mofetil—psoriasis	0.0001	0.000555	CcSEcCtD
Levomilnacipran—Skin disorder—Prednisone—psoriasis	9.96e-05	0.000552	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisone—psoriasis	9.91e-05	0.00055	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	9.9e-05	0.00285	CbGpPWpGaD
Levomilnacipran—Vision blurred—Methotrexate—psoriasis	9.89e-05	0.000549	CcSEcCtD
Levomilnacipran—Asthenia—Hydrocortisone—psoriasis	9.89e-05	0.000548	CcSEcCtD
Levomilnacipran—Vomiting—Cyclosporine—psoriasis	9.86e-05	0.000547	CcSEcCtD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.79e-05	0.00281	CbGpPWpGaD
Levomilnacipran—Rash—Cyclosporine—psoriasis	9.78e-05	0.000542	CcSEcCtD
Levomilnacipran—Anorexia—Prednisone—psoriasis	9.77e-05	0.000542	CcSEcCtD
Levomilnacipran—Dermatitis—Cyclosporine—psoriasis	9.77e-05	0.000542	CcSEcCtD
Levomilnacipran—Pruritus—Hydrocortisone—psoriasis	9.75e-05	0.000541	CcSEcCtD
Levomilnacipran—Headache—Cyclosporine—psoriasis	9.71e-05	0.000539	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Betamethasone—psoriasis	9.63e-05	0.000534	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dexamethasone—psoriasis	9.63e-05	0.000534	CcSEcCtD
Levomilnacipran—Vomiting—Mycophenolate mofetil—psoriasis	9.62e-05	0.000533	CcSEcCtD
Levomilnacipran—Hypersensitivity—Triamcinolone—psoriasis	9.56e-05	0.00053	CcSEcCtD
Levomilnacipran—Rash—Mycophenolate mofetil—psoriasis	9.54e-05	0.000529	CcSEcCtD
Levomilnacipran—Dermatitis—Mycophenolate mofetil—psoriasis	9.53e-05	0.000528	CcSEcCtD
Levomilnacipran—Headache—Mycophenolate mofetil—psoriasis	9.47e-05	0.000525	CcSEcCtD
Levomilnacipran—Diarrhoea—Hydrocortisone—psoriasis	9.43e-05	0.000523	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—psoriasis	9.4e-05	0.000521	CcSEcCtD
Levomilnacipran—Urticaria—Betamethasone—psoriasis	9.35e-05	0.000519	CcSEcCtD
Levomilnacipran—Urticaria—Dexamethasone—psoriasis	9.35e-05	0.000519	CcSEcCtD
Levomilnacipran—Dizziness—Prednisolone—psoriasis	9.33e-05	0.000517	CcSEcCtD
Levomilnacipran—Asthenia—Triamcinolone—psoriasis	9.31e-05	0.000516	CcSEcCtD
Levomilnacipran—Body temperature increased—Dexamethasone—psoriasis	9.31e-05	0.000516	CcSEcCtD
Levomilnacipran—Abdominal pain—Dexamethasone—psoriasis	9.31e-05	0.000516	CcSEcCtD
Levomilnacipran—Abdominal pain—Betamethasone—psoriasis	9.31e-05	0.000516	CcSEcCtD
Levomilnacipran—Body temperature increased—Betamethasone—psoriasis	9.31e-05	0.000516	CcSEcCtD
Levomilnacipran—Insomnia—Prednisone—psoriasis	9.27e-05	0.000514	CcSEcCtD
Levomilnacipran—Nausea—Cyclosporine—psoriasis	9.21e-05	0.000511	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisone—psoriasis	9.21e-05	0.000511	CcSEcCtD
Levomilnacipran—Pruritus—Triamcinolone—psoriasis	9.18e-05	0.000509	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—LEP—psoriasis	9.12e-05	0.00262	CbGpPWpGaD
Levomilnacipran—Dizziness—Hydrocortisone—psoriasis	9.11e-05	0.000505	CcSEcCtD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.11e-05	0.00262	CbGpPWpGaD
Levomilnacipran—Convulsion—Methotrexate—psoriasis	9.1e-05	0.000504	CcSEcCtD
Levomilnacipran—Dyspepsia—Prednisone—psoriasis	9.02e-05	0.0005	CcSEcCtD
Levomilnacipran—Nausea—Mycophenolate mofetil—psoriasis	8.98e-05	0.000498	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—psoriasis	8.94e-05	0.000496	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—psoriasis	8.91e-05	0.000494	CcSEcCtD
Levomilnacipran—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.91e-05	0.00256	CbGpPWpGaD
Levomilnacipran—Rash—Prednisolone—psoriasis	8.9e-05	0.000493	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisolone—psoriasis	8.89e-05	0.000493	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.88e-05	0.000492	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL10—psoriasis	8.86e-05	0.00255	CbGpPWpGaD
Levomilnacipran—Fatigue—Prednisone—psoriasis	8.84e-05	0.00049	CcSEcCtD
Levomilnacipran—Headache—Prednisolone—psoriasis	8.84e-05	0.00049	CcSEcCtD
Levomilnacipran—Constipation—Prednisone—psoriasis	8.77e-05	0.000486	CcSEcCtD
Levomilnacipran—Vomiting—Hydrocortisone—psoriasis	8.76e-05	0.000486	CcSEcCtD
Levomilnacipran—Rash—Hydrocortisone—psoriasis	8.69e-05	0.000482	CcSEcCtD
Levomilnacipran—Dermatitis—Hydrocortisone—psoriasis	8.68e-05	0.000481	CcSEcCtD
Levomilnacipran—Headache—Hydrocortisone—psoriasis	8.63e-05	0.000479	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL4—psoriasis	8.62e-05	0.00248	CbGpPWpGaD
Levomilnacipran—Dizziness—Triamcinolone—psoriasis	8.58e-05	0.000476	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—psoriasis	8.51e-05	0.000472	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	8.5e-05	0.00244	CbGpPWpGaD
Levomilnacipran—Asthenia—Betamethasone—psoriasis	8.45e-05	0.000468	CcSEcCtD
Levomilnacipran—Asthenia—Dexamethasone—psoriasis	8.45e-05	0.000468	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-B—psoriasis	8.43e-05	0.00242	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	8.42e-05	0.00242	CbGpPWpGaD
Levomilnacipran—Nervous system disorder—Methotrexate—psoriasis	8.4e-05	0.000466	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—psoriasis	8.39e-05	0.000465	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Prednisone—psoriasis	8.38e-05	0.000465	CcSEcCtD
Levomilnacipran—Nausea—Prednisolone—psoriasis	8.38e-05	0.000465	CcSEcCtD
Levomilnacipran—Pruritus—Dexamethasone—psoriasis	8.33e-05	0.000462	CcSEcCtD
Levomilnacipran—Pruritus—Betamethasone—psoriasis	8.33e-05	0.000462	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—psoriasis	8.32e-05	0.000462	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—psoriasis	8.28e-05	0.000459	CcSEcCtD
Levomilnacipran—Vomiting—Triamcinolone—psoriasis	8.25e-05	0.000457	CcSEcCtD
Levomilnacipran—Nausea—Hydrocortisone—psoriasis	8.18e-05	0.000454	CcSEcCtD
Levomilnacipran—Rash—Triamcinolone—psoriasis	8.18e-05	0.000454	CcSEcCtD
Levomilnacipran—Dermatitis—Triamcinolone—psoriasis	8.17e-05	0.000453	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—psoriasis	8.17e-05	0.000453	CcSEcCtD
Levomilnacipran—Urticaria—Prednisone—psoriasis	8.14e-05	0.000452	CcSEcCtD
Levomilnacipran—Headache—Triamcinolone—psoriasis	8.13e-05	0.000451	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—psoriasis	8.1e-05	0.000449	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—psoriasis	8.1e-05	0.000449	CcSEcCtD
Levomilnacipran—Diarrhoea—Dexamethasone—psoriasis	8.05e-05	0.000447	CcSEcCtD
Levomilnacipran—Diarrhoea—Betamethasone—psoriasis	8.05e-05	0.000447	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—psoriasis	8.01e-05	0.000444	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	7.95e-05	0.00228	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.85e-05	0.00226	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.81e-05	0.00225	CbGpPWpGaD
Levomilnacipran—Dizziness—Dexamethasone—psoriasis	7.78e-05	0.000432	CcSEcCtD
Levomilnacipran—Dizziness—Betamethasone—psoriasis	7.78e-05	0.000432	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—psoriasis	7.75e-05	0.00043	CcSEcCtD
Levomilnacipran—Nausea—Triamcinolone—psoriasis	7.71e-05	0.000427	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—psoriasis	7.69e-05	0.000427	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.68e-05	0.00221	CbGpPWpGaD
Levomilnacipran—Dyspnoea—Methotrexate—psoriasis	7.64e-05	0.000424	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—psoriasis	7.62e-05	0.000422	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisone—psoriasis	7.55e-05	0.000419	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—psoriasis	7.54e-05	0.000418	CcSEcCtD
Levomilnacipran—Vomiting—Betamethasone—psoriasis	7.48e-05	0.000415	CcSEcCtD
Levomilnacipran—Vomiting—Dexamethasone—psoriasis	7.48e-05	0.000415	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—psoriasis	7.45e-05	0.000413	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.42e-05	0.00213	CbGpPWpGaD
Levomilnacipran—Rash—Dexamethasone—psoriasis	7.42e-05	0.000412	CcSEcCtD
Levomilnacipran—Rash—Betamethasone—psoriasis	7.42e-05	0.000412	CcSEcCtD
Levomilnacipran—Dermatitis—Dexamethasone—psoriasis	7.42e-05	0.000411	CcSEcCtD
Levomilnacipran—Dermatitis—Betamethasone—psoriasis	7.42e-05	0.000411	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—psoriasis	7.4e-05	0.00041	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—psoriasis	7.39e-05	0.00041	CcSEcCtD
Levomilnacipran—Headache—Dexamethasone—psoriasis	7.37e-05	0.000409	CcSEcCtD
Levomilnacipran—Headache—Betamethasone—psoriasis	7.37e-05	0.000409	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—psoriasis	7.36e-05	0.000408	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—psoriasis	7.25e-05	0.000402	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	7.14e-05	0.00205	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	7.12e-05	0.00205	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Prednisone—psoriasis	7.01e-05	0.000389	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—psoriasis	7.01e-05	0.000389	CcSEcCtD
Levomilnacipran—Nausea—Betamethasone—psoriasis	6.99e-05	0.000388	CcSEcCtD
Levomilnacipran—Nausea—Dexamethasone—psoriasis	6.99e-05	0.000388	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.91e-05	0.00199	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	6.9e-05	0.00198	CbGpPWpGaD
Levomilnacipran—Urticaria—Methotrexate—psoriasis	6.81e-05	0.000377	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	6.79e-05	0.00195	CbGpPWpGaD
Levomilnacipran—Dizziness—Prednisone—psoriasis	6.78e-05	0.000376	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—psoriasis	6.77e-05	0.000376	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—psoriasis	6.77e-05	0.000376	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.64e-05	0.00191	CbGpPWpGaD
Levomilnacipran—Vomiting—Prednisone—psoriasis	6.52e-05	0.000361	CcSEcCtD
Levomilnacipran—Rash—Prednisone—psoriasis	6.46e-05	0.000358	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisone—psoriasis	6.46e-05	0.000358	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—CARM1—psoriasis	6.44e-05	0.00185	CbGpPWpGaD
Levomilnacipran—Headache—Prednisone—psoriasis	6.42e-05	0.000356	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—psoriasis	6.31e-05	0.00035	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—psoriasis	6.15e-05	0.000341	CcSEcCtD
Levomilnacipran—Nausea—Prednisone—psoriasis	6.09e-05	0.000338	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—psoriasis	6.06e-05	0.000336	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.03e-05	0.00173	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.02e-05	0.00173	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Methotrexate—psoriasis	5.86e-05	0.000325	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—psoriasis	5.67e-05	0.000314	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—JUN—psoriasis	5.64e-05	0.00162	CbGpPWpGaD
Levomilnacipran—Vomiting—Methotrexate—psoriasis	5.45e-05	0.000302	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—psoriasis	5.4e-05	0.0003	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—psoriasis	5.4e-05	0.000299	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—psoriasis	5.37e-05	0.000298	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IFNG—psoriasis	5.21e-05	0.0015	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.2e-05	0.0015	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	5.17e-05	0.00149	CbGpPWpGaD
Levomilnacipran—Nausea—Methotrexate—psoriasis	5.09e-05	0.000282	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.85e-05	0.00139	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.54e-05	0.00131	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	4.17e-05	0.0012	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.99e-05	0.00115	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CAT—psoriasis	3.96e-05	0.00114	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.94e-05	0.00113	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NDUFA5—psoriasis	3.87e-05	0.00111	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—psoriasis	3.72e-05	0.00107	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.61e-05	0.00104	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NDUFA5—psoriasis	3.45e-05	0.000993	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—psoriasis	3.41e-05	0.000979	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—psoriasis	3.37e-05	0.00097	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NDUFA5—psoriasis	3.37e-05	0.000969	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.35e-05	0.000964	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP2S1—psoriasis	3.29e-05	0.000946	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.22e-05	0.000926	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NDUFA5—psoriasis	3.18e-05	0.000913	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.13e-05	0.000901	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—APOE—psoriasis	3.08e-05	0.000885	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.99e-05	0.000859	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP2S1—psoriasis	2.94e-05	0.000844	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP2S1—psoriasis	2.87e-05	0.000824	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP2S1—psoriasis	2.7e-05	0.000777	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPARG—psoriasis	2.68e-05	0.00077	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.22e-05	0.000639	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.14e-05	0.000615	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NDUFA5—psoriasis	2.08e-05	0.000597	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.94e-05	0.000558	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP2S1—psoriasis	1.77e-05	0.000508	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.72e-05	0.000496	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.66e-05	0.000479	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CARM1—psoriasis	1.61e-05	0.000462	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.54e-05	0.000443	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.5e-05	0.000432	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.47e-05	0.000422	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CARM1—psoriasis	1.43e-05	0.000412	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CARM1—psoriasis	1.4e-05	0.000403	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.34e-05	0.000385	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CARM1—psoriasis	1.32e-05	0.000379	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CAT—psoriasis	9.89e-06	0.000284	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CAT—psoriasis	8.82e-06	0.000254	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CARM1—psoriasis	8.63e-06	0.000248	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CAT—psoriasis	8.61e-06	0.000248	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CAT—psoriasis	8.12e-06	0.000233	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOE—psoriasis	7.68e-06	0.000221	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOE—psoriasis	6.86e-06	0.000197	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOE—psoriasis	6.69e-06	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARG—psoriasis	6.69e-06	0.000192	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOE—psoriasis	6.31e-06	0.000181	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARG—psoriasis	5.97e-06	0.000172	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARG—psoriasis	5.83e-06	0.000168	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARG—psoriasis	5.49e-06	0.000158	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CAT—psoriasis	5.31e-06	0.000153	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOE—psoriasis	4.12e-06	0.000119	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARG—psoriasis	3.59e-06	0.000103	CbGpPWpGaD
